NCT05763329View on ClinicalTrials.gov

Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

June 30, 2025

Conditions
OSA
Interventions
DRUG

Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1

Patients will receive Lemborexant 5 mg per day on the first day of sleep test

DRUG

Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2

Patients will receive Lemborexant 5 mg per day on the second day of sleep test

DRUG

Placebo Day 1

Patients will receive placebo on the first day of sleep test

DRUG

Placebo Day 2

Patients will receive placebo on the second day of sleep test

Trial Locations (1)

10330

Chulalongkorn University, Pathum Wan

All Listed Sponsors
lead

Chulalongkorn University

OTHER